TuisSDZ • SWX
add
Sandoz Group AG
Vorige sluiting
CHFÂ 57,70
Dagwisseling
CHFÂ 57,46 - CHFÂ 57,92
Jaarwisseling
CHFÂ 26,25 - CHFÂ 59,86
Markkapitalisasie
25,44Â mjd CHF
Gemiddelde volume
742,58Â k
P/V-verhouding
141,94
Dividend-opbrengs
1,04%
PrimĂŞre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 2,63Â mjd | 4,01% |
Bedryfskoste | 904,50Â m | -11,67% |
Netto inkomste | 188,50Â m | 151,33% |
Netto winsgrens | 7,16 | 141,89% |
Wins per aandeel | — | — |
EBITDA | 415,00Â m | 53,42% |
Effektiewe belastingkoers | 25,20% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,39Â mjd | 98,15% |
Totale bates | 21,61Â mjd | 11,86% |
Totale aanspreeklikheid | 12,79Â mjd | 16,79% |
Totale ekwiteit | 8,82 mjd | — |
Uitstaande aandele | 432,00 m | — |
Prys om te bespreek | 2,83 | — |
Opbrengs op bates | 3,48% | — |
Opbrengs op kapitaal | 5,18% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 188,50Â m | 151,33% |
Kontant van bedrywe | 261,50Â m | 128,38% |
Kontant van beleggings | -158,00Â m | 19,80% |
Kontant van finansiering | -74,00Â m | 35,09% |
Netto kontantverandering | 99,00Â m | 148,53% |
Beskikbare kontantvloei | 151,94Â m | 47,69% |
Meer oor
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars. Wikipedia
Gestig
1886
Webwerf
Werknemers
20Â 000